Highly experienced researcher in the neuroscience area (over 25 years' experience), Co-Founder and Chief Scientific Officer of a neuroscience-oriented bioscience company (Neurolixis) developing clinical-stage drugs for treatment of Parkinson's disease and Rett syndrome. Prior to joining Neurolixis, Adrian was Director of Neurobiology at Pierre Fabre Laboratories where he identified novel antipsychotic, antidepressant and analgesic drug candidates. Prior to Pierre Fabre, Adrian investigated signal transduction mechanisms of monoamine receptors at the Servier Research Institute.
Drugs characterized in the course of Adrian's work include milnacipran (Savella 庐), piribedil (Trivastal 庐), agom...
We鈥檝e updated our privacy policy so that we are compliant with changing global privacy regulations and to provide you with insight into the limited ways in which we use your data.
You can read the details below. By accepting, you agree to the updated privacy policy.
